Emcure expands injectables capacity, opens 3rd facility in Gujarat
时间:2024-06-02 03:38:13 阅读(143)
The third injectable facility of Emcure Pharmaceuticals in Mehsana, Gujarat, which was commissioned in August 2023, is now ready for commercial supplies to domestic and international markets. The company already has an oral formulations manufacturing line in Mehsana.
It also has a facility in Hinjawadi, Pune, with a capacity of 80.64 million vials per annum and another in Sanand, Gujarat, with a capacity to churn out 72 million vials per annum.
IPO-bound Emcure’s manufacturing operations cover oral solids, oral liquids and injectables, including liposomal and lyophilized injectables, biotherapeutics and complex APIs. The company’s subsidiary Gennova Biopharmaceuticals,also plans to use its mRNA platform, through which it launched the Covid-19 vaccine, forthree other vaccines for Zoster, Zika and Rabies.
Emcure’s injectable portfolio includes complex iron injectables, oncology, steroids, suspensions and emulsions. Emcure can produce high-potency injectables, particularly oncology products.
Emcure had filed a draft red herring prospectus (DRHP) on December 16 for its Rs 800 crore IPO. It is the 12th largest Indian pharmaceutical company and the largest pharmaceutical company in the gynaecology, blood-related and HIV antiviral therapeutics segment in the country.
For the international markets, the firm’s focus is on developing and commercialising products, which requires significant expertise and is subject to less competition and offers higher margins.
In Europe and other key target markets, they are focused on higher-value-added generics and complex injectables, such as Cidofovir and Meropenem. Europe is one of the focus areas in the hospital segment, as it is a large market for complex injectables products, such as Cidofovir, BiCNU and Treprostinil, the company’s DRHP said.
The company is working on `ready-to-use’ products that reduce multi-step dose preparation and enable ease of use by physicians.
猜你喜欢
- Share Market Highlights- Nifty settles above 17900, Sensex jumps 350 pts; Bank Nifty above 43000, Bajaj shares gain
- Share Market Highlights- Nifty under 17950, Sensex down 300 pts, snap 3-day winning streak; Bank Nifty 1
- Share Market Highlights- Nifty settles near 21,450, Sensex above 71,400; FMCG index gains more than 1%
- Rupee to depreciate on strong dollar, elevated crude prices; USDINR to trade in this range
- IOC market share climbs to 43%, posts ‘stellar’ performance in FY23
- Share Market Highlights- Nifty 50 ends above 19460, Sensex climbs 130 pts; Bank Nifty below 43950, Tata Steel, Adani Ports fall
- ITC, HCL Tech, Adani Ports, Equitas Small Finance Bank, IndusInd Bank, NBCC stocks in focus
- Share Market Highlights- Nifty settles above 18100, Sensex jumps 240 pts; Bank Nifty above 43350, ONGC, TechM shares gain
- Rupee slumps 76 paise to close at 82